Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · Chief Executive Officer | November 19, 2024 | November 20, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date November 19, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 723,363 |
Reported balance
After 2024-11-19 transaction · row 1
1 source rowRow 1 · 2024-11-19 · Sale · Disposed 8,706 · Balance 723,363 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,904 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 3,904 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 26, 2026 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 4,000 | $0.00 Strike: $57.66 | $0.00 |
DisclosureSEC source: 0001193125-26-403099 · ownership.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-09-22 F4 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. Read SEC document |
| September 23, 2026 Filed Sep 26, 2026 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-403099 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,904 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 23, 2026. F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 23:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 8,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001193125-25-227233 · ownership.xml · derivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,706 | $0.55 | $4,775.24 |
DisclosureSEC source: 0000950170-24-129257 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 723,363 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,609 | $0.86 | $9,175.72 |
DisclosureSEC source: 0000950170-24-122336 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,069 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,752 | $0.78 | $7,596.81 |
DisclosureSEC source: 0000950170-24-116645 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 742,678 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,493 | $0.81 | $1,216.50 |
DisclosureSEC source: 0000950170-24-112912 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,430 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| September 18, 2024 Filed Jan 18, 2025 01:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-006883 · ownership.xml · derivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-09-17 F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,390 | $0.74 | $3,995.61 |
DisclosureSEC source: 0000950170-24-099846 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 753,923 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7384 to $0.745. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,091 | $0.76 | $2,347.61 |
DisclosureSEC source: 0000950170-24-099102 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 759,313 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,847 | $0.73 | $7,970.38 |
DisclosureSEC source: 0000950170-24-092807 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762,404 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 16:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,731 | $0.75 | $7,299.22 |
DisclosureSEC source: 0000950170-24-085669 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,251 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 16:11 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,489 | $0.72 | $1,072.08 |
DisclosureSEC source: 0000950170-24-081511 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 782,982 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| May 21, 2024 Filed May 23, 2024 17:24 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,149 | $0.79 | $4,079.55 |
DisclosureSEC source: 0000950170-24-064052 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,471 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7899 to $0.7994. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 17, 2024 Filed May 21, 2024 16:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,075 | $0.75 | $2,304.10 |
DisclosureSEC source: 0000950170-24-062982 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,620 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 03, 2024 Filed May 7, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,240 | $0.80 | $8,151.04 |
DisclosureSEC source: 0000950170-24-054512 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,695 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,601 | $0.75 | $7,206.51 |
DisclosureSEC source: 0000950170-24-046908 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 802,935 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,533 | $0.77 | $1,183.48 |
DisclosureSEC source: 0000950170-24-041810 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,536 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 16:18 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,155 | $0.71 | $3,650.26 |
DisclosureSEC source: 0000950170-24-018785 · ownership.xml · nonDerivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,069 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7002 to $0.7098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:18 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,097 | $0.70 | $2,153.03 |
DisclosureSEC source: 0000950170-24-018785 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 819,224 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 16:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 41,421 | $0.67 | $27,752.07 |
DisclosureSEC source: 0000950170-24-011769 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,321 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 9,500 | $0.67 | $6,368.80 |
DisclosureSEC source: 0000950170-24-007406 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,742 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6794. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 16:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,664 | $0.64 | $1,063.30 |
DisclosureSEC source: 0000950170-24-002935 · ownership.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 873,242 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,382 | $1.69 | $7,407.77 |
DisclosureSEC source: 0001209191-23-056313 · doc4.xml · nonDerivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 874,906 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.69 to $1.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,689 | $1.63 | $4,386.03 |
DisclosureSEC source: 0001209191-23-056313 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 879,288 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,581 | $1.58 | $13,557.98 |
DisclosureSEC source: 0001209191-23-053349 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 881,977 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,325 | $1.98 | $2,618.60 |
DisclosureSEC source: 0001209191-23-052229 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 890,558 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 85,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-050221 · doc4.xml · derivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-09-18 F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,055 | $2.79 | $11,312.64 |
DisclosureSEC source: 0001209191-23-046732 · doc4.xml · nonDerivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,883 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.77 to $2.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 11,361 | $2.50 | $28,351.38 |
DisclosureSEC source: 0001209191-23-046732 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 895,938 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,342 | $3.56 | $29,710.03 |
DisclosureSEC source: 0001209191-23-043121 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 907,299 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,275 | $3.05 | $16,062.90 |
DisclosureSEC source: 0001209191-23-041583 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 915,641 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.96 to $3.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Includes 4,288 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| May 18, 2023 Filed May 19, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,536 | $4.21 | $19,114.70 |
DisclosureSEC source: 0001209191-23-031074 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 916,628 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.04 to $4.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 8,408 | $3.71 | $31,182.75 |
DisclosureSEC source: 0001209191-23-025114 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 921,164 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,122 | $6.63 | $33,935.30 |
DisclosureSEC source: 0001209191-23-012250 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 929,572 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.54 to $6.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 617,500 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-23-006988 · doc4.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,836,875 Underlying: Common Stock · 617,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 17:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 332,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006988 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,964 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 19:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 34,435 | $5.08 | $174,850.60 |
DisclosureSEC source: 0001209191-23-004499 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,607 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Includes 3,009 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 17:47 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,515 | $7.27 | $32,810.05 |
DisclosureSEC source: 0000899243-22-036553 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,033 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.23 to $7.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-22-050809 · doc4.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2030-09-15 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050809 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,560 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 16, 2022. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 16:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 4,564 | $7.76 | $35,428.51 |
DisclosureSEC source: 0000899243-22-029271 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,548 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.67 to $7.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 17:59 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029046 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,112 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 07:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 89,375 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-22-025231 · doc4.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,375 Underlying: Common Stock · 89,375 shares Expires 2032-07-01 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 07:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 48,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025231 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,112 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. F2 · balance_after: Includes 1,822 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| May 18, 2022 Filed May 23, 2022 16:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 29,135 | $4.33 | $126,256.52 |
DisclosureSEC source: 0000899243-22-019216 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,165 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.19 to $4.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 16:23 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 585,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0000899243-22-013332 · doc4.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,000 Underlying: Common Stock · 585,000 shares Expires 2032-01-18 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 16:23 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 315,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013332 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,300 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 36,720 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-21-064508 · doc4.xml · derivative · entry 2 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,720 Underlying: Common Stock · 36,720 shares Expires 2029-11-10 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the three-year period beginning on November 11, 2021. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 18,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-064508 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests over three years in equal annual installments beginning on November 11, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.